United Therapeutics (UTHR) Income from Continuing Operations (2009 - 2026)
United Therapeutics (UTHR) recorded Income from Continuing Operations of $333 million in Q2 2026, up 7.6% from $309.5 million a year earlier and up 21.1% from the prior quarter.
Powered by 
Analysis
United Therapeutics (UTHR) Income from Continuing Operations (2009 - 2026) Analysis & Trends
On a TTM basis, United Therapeutics' Income from Continuing Operations came in at $1.31 billion as of Jun 30, 2026, up 5.5% year-over-year; for FY2025, it was $1.33 billion, up 11.7% from FY2024.
- Annual Income from Continuing Operations has increased for four straight years, with a five-year compound annual growth rate of 21.0% (FY2020 to FY2025).
- Across earlier years, Income from Continuing Operations came in at $1.2 billion in FY2024 (+21.4%), $984.8 million in FY2023 (+35.4%), $727.3 million in FY2022 (+52.9%) and $475.8 million in FY2021 (-7.6%).
- Quarterly Income from Continuing Operations has ranged from $112.2 million in Q4 2021 to $364.3 million in Q4 2025 over the past five years.
- On a year-over-year basis, Income from Continuing Operations rose in seven of the last eight quarters, with growth averaging 11.8%.
- Peak year-over-year performance for Income from Continuing Operations in the last five years was growth of 747.7% in Q1 2022, against a decline of 32.8% in Q2 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $274.9 million (Q1 2026), $364.3 million (Q4 2025) and $338.7 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | United Therapeutics | 23.13 Bn | 12.62 Bn | 683.80 Mn | 333.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 333.00 Mn |
| Mar 31, 2026 | 274.90 Mn |
| Dec 31, 2025 | 364.30 Mn |
| Sep 30, 2025 | 338.70 Mn |
| Jun 30, 2025 | 309.50 Mn |
| Mar 31, 2025 | 322.20 Mn |
| Dec 31, 2024 | 301.30 Mn |
| Sep 30, 2024 | 309.10 Mn |
| Jun 30, 2024 | 278.10 Mn |
| Mar 31, 2024 | 306.60 Mn |
| Dec 31, 2023 | 217.10 Mn |
| Sep 30, 2023 | 267.60 Mn |
| Jun 30, 2023 | 259.20 Mn |
| Mar 31, 2023 | 240.90 Mn |
| Dec 31, 2022 | 132.10 Mn |
| Sep 30, 2022 | 239.30 Mn |
| Jun 30, 2022 | 116.00 Mn |
| Mar 31, 2022 | 239.90 Mn |
| Dec 31, 2021 | 112.20 Mn |
| Sep 30, 2021 | 162.70 Mn |
API Access
United Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=UTHR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "UTHR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=UTHR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();